Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
MedtronicNeuro
ClinicalTrials.gov Identifier:
NCT00101933
First received: January 18, 2005
Last updated: February 12, 2014
Last verified: February 2014
  Purpose

The purpose of this research is to study the safety and effectiveness of bilateral stimulation of the anterior nucleus of the thalamus as adjunctive therapy for reducing the frequency of seizures in adults diagnosed with epilepsy characterized by partial-onset seizures, with or without secondary generalization, that are refractory to antiepileptic medications.


Condition Intervention Phase
Epilepsy
Device: Medtronic DBS Therapy for epilepsy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy

Resource links provided by NLM:


Further study details as provided by MedtronicNeuro:

Primary Outcome Measures:
  • Primary Analysis: Change in Seizure Rate [ Time Frame: Through the end of the three-month blinded phase ] [ Designated as safety issue: No ]
    A protocol-prespecified generalized estimating equations (GEE) analysis was used to evaluate the treatment effect on seizure frequency. The final GEE model for the primary objective evaluation included treatment effect, log of the baseline seizure count, log of age, visit (categorical), treatment-by-visit interaction (categorical), and the offset (the number of days the diary was recorded in each month).

  • Alternative Primary Analysis: Change in Seizure Rate [ Time Frame: Through the end of the three-month blinded phase ] [ Designated as safety issue: No ]
    A generalized estimating equations (GEE) analysis was used to evaluate the treatment effect on seizure frequency. With one outlier subject removed, the GEE model for this alternative analysis included treatment effect, log of the baseline seizure count, log of age, visit (categorical), and the offset (the number of days the diary was recorded in each month).


Secondary Outcome Measures:
  • Adverse Events Experienced With the Medtronic DBS System [ Time Frame: Through Year 2 of the long-term follow-up phase ] [ Designated as safety issue: Yes ]

    The results are for the follow-up after device implantation through Year 2 and summarized are events that occurred in greater than 5% of subjects. Only events related to the device, therapy, or surgery are included. These abbreviations were used:

    • General dis...=General disorders and administration site conditions
    • Injury, poison...=Injury, poisoning and procedural complications
    • Ther.=Therapeutic.

    For this summary, adverse events are reported as 'MedDRA System Organ Class - adverse event'.


  • Incidence of Sudden Unexplained Death in Epilepsy (SUDEP) [ Time Frame: Inclusive of all study follow-up after device implantation (mean follow-up 3.7 years) ] [ Designated as safety issue: Yes ]

    The number presented is for Definite and Probable SUDEP. The rate is calculated per 1000 subject years of follow-up. The confidence interval is the 95% Poisson confidence interval. Per protocol, only definite and probable SUDEP classifications were included in the calculation.

    The results shown are for the entire study follow-up after device implantation.


  • Seizure Responder Rate [ Time Frame: Through the end of the three-month blinded phase ] [ Designated as safety issue: No ]
    A responder is defined as a subject with greater than or equal to 50% reduction in seizures as compared with baseline.

  • Change in Percentage of Days Seizure-free [ Time Frame: Through the end of the three-month blinded phase ] [ Designated as safety issue: No ]
    Difference between active group and control group in percentage change in seizure-free days over the entire blinded phase as compared to the entire baseline phase. The number of seizure-free days was normalized to 84-day baseline and blinded phases for each subject.

  • Percentage Change in the Maximum Length of Seizure-free Intervals [ Time Frame: Through the end of the three-month blinded phase ] [ Designated as safety issue: No ]
    Difference between active group and control group in percentage change in the maximum length of seizure-free intervals over the entire blinded phase as compared to the entire baseline phase.

  • Proportion of Treatment Failures [ Time Frame: Through the end of the three-month blinded phase ] [ Designated as safety issue: No ]
    A treatment failure was defined in the protocol as a subject who 1) required 3 or more doses of rescue medication within 48 hours, 3 times during the blinded phase; or 2) had 3 episodes of convulsive status epilepticus during the blinded phase.


Other Outcome Measures:
  • Change in Most Severe Seizures [ Time Frame: Through the end of the three-month blinded phase ] [ Designated as safety issue: No ]
    Seizures were recorded on daily seizure diaries. The subject recorded the number of seizures by seizure type on the seizure diary. The subject also noted at baseline, of those they had ever experienced, which seizure they considered to be "most severe."


Enrollment: 157
Study Start Date: December 2003
Estimated Study Completion Date: October 2015
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Active Stimulation
Device: Medtronic DBS Therapy for epilepsy
Stimulation On
Sham Comparator: 2
No Stimulation
Device: Medtronic DBS Therapy for epilepsy
Stimulation Off

Detailed Description:

Medtronic, Inc. is sponsoring an investigational study of the Medtronic DBS Therapy for epilepsy, the company's deep brain stimulation (DBS) therapy for patients with refractory epilepsy. Epilepsy is a condition that affects 2.3 million Americans, and about one-third of these patients are refractory, or continue to experience seizures despite a wide range of treatment options.

The prospective, randomized, double-blind trial uses existing technology to test whether bilateral stimulation of the anterior nucleus of the thalamus can safely and effectively reduce seizure frequency in patients with epilepsy. It includes enrollment of 157 patients at 17 sites in the U.S. 110 patients were implanted and monitored for 13 months following implant, with long-term follow-up until the device is approved or the study is stopped. 109 of the 110 implanted subjects were randomized to Active stimulation or Control.

Patients in the active group, who received neurostimulation, were monitored for a reduction in seizure rates compared to the control group, who did not receive neurostimulation during the three-month double-blind phase. After the double-blind phase, all patients received neurostimulation.

Candidates for the trial were adults with partial-onset epilepsy for whom at least three antiepileptic drugs have proven ineffective. They were to have had an average of six or more seizures per month. Candidates continued to receive their epilepsy medications while participating in the trial.

Deep brain stimulation therapy has already received approval in the United States, Europe, Canada, and Australia for the treatment of Essential Tremor and Parkinson's disease. Deep brain stimulation is not approved in the United States for the treatment of epilepsy.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Relevant Inclusion and Exclusion Criteria are listed below.

Inclusion Criteria

  • Partial-onset seizures with or without secondary generalization. The final determination shall be made by the Investigator based on a clinical description of the seizures and previous diagnostic testing that includes, at a minimum, video/clinical EEG that captured at least one ictal event.
  • Anticipated average of 6 or more partial-onset seizures (with or without secondary generalized seizures) per month during the Baseline Phase, with no more than 30 days between seizures during the Baseline Phase.
  • Refractory to antiepileptic drugs (AEDs). Patients will be considered refractory if they have failed at least three AEDs due to lack of efficacy.
  • Receiving one to four currently marketed AEDs
  • Be between 18 and 65 years of age at the time of lead implant

Exclusion Criteria:

  • Multilobar (>3 different lobes) anatomic areas of seizure onset
  • Symptomatic generalized epilepsy
  • Previous diagnosis of psychogenic/non-epileptic seizures
  • Presence of implanted electrical stimulation medical device anywhere in the body (e.g., cardiac pacemakers, spinal cord stimulator) or any metallic implants in the head (e.g., aneurysm clip, cochlear implant). Vagal nerve stimulators are allowed if the device has been turned off for at least 30 days prior to the Baseline Week -12 visit and the patient agrees to have the generator explanted prior to or at the time of the Kinetra Neurostimulator implant.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided